736 related articles for article (PubMed ID: 26597956)
21. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
22. GLP-1 Agonists in Type 1 Diabetes Mellitus.
Janzen KM; Steuber TD; Nisly SA
Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
[TBL] [Abstract][Full Text] [Related]
23. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
Hughes E
Prim Care Diabetes; 2016 Jun; 10(3):202-9. PubMed ID: 26776758
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.
Balena R; Hensley IE; Miller S; Barnett AH
Diabetes Obes Metab; 2013 Jun; 15(6):485-502. PubMed ID: 23061470
[TBL] [Abstract][Full Text] [Related]
25. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
[TBL] [Abstract][Full Text] [Related]
26. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.
Thong KY; Jose B; Sukumar N; Cull ML; Mills AP; Sathyapalan T; Shafiq W; Rigby AS; Walton C; Ryder RE;
Diabetes Obes Metab; 2011 Aug; 13(8):703-10. PubMed ID: 21410858
[TBL] [Abstract][Full Text] [Related]
27. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
Charbonnel PB
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
[No Abstract] [Full Text] [Related]
28. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Lane W; Weinrib S; Rappaport J
Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
30. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
[TBL] [Abstract][Full Text] [Related]
31. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
32. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
33. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
34. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
Tanaka K; Okada Y; Tokutsu A; Tanaka Y
Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
[TBL] [Abstract][Full Text] [Related]
36. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
37. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
[TBL] [Abstract][Full Text] [Related]
38. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G
Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708
[TBL] [Abstract][Full Text] [Related]
39. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.
Katout M; Zhu H; Rutsky J; Shah P; Brook RD; Zhong J; Rajagopalan S
Am J Hypertens; 2014 Jan; 27(1):130-9. PubMed ID: 24263424
[TBL] [Abstract][Full Text] [Related]
40. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
